To tackle a broad range of metabolic disorders in relation to vascular damage in ADPKD, clinical trials have been conducted with angiotensin-converting enzyme (ACE) inhibitors in ADPKD patients (31, 67). This evidence concerns the gene ACE and metabolic disease.